Home Casteddu.com	FAQ My Amedeo About	Flying Publisher
	The Medical Article of the Year 2008: Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661-78. Free full-text

Drug Resistance

Free Subscription Articles published in Antivir Ther Retrieve available abstracts of 82 articles: HTML format

Single Articles

January 2008
1. PEREZ H , Vignoles M, Laufer N, Gomez A, et al
   Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen.
   Antivir Ther. 2008;13:135-9.
   PubMed     Related articles    Abstract available
   
   
   
2. SYLLA M , Chamberland A, Boileau C, Traore HA, et al
   Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso.
   Antivir Ther. 2008;13:141-8.
   PubMed     Related articles    Abstract available
   
   
   
3. FRANGEUL A , Bussetta C, Deval J, Barral K, et al
   Gln151 of HIV-1 reverse transcriptase acts as a steric gate towards clinically relevant acyclic phosphonate nucleotide analogues.
   Antivir Ther. 2008;13:115-24.
   PubMed     Related articles    Abstract available
   
   
   
4. SHELDON J , Ramos B, Toro C, Rios P, et al
   Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?
   Antivir Ther. 2008;13:97-102.
   PubMed     Related articles    Abstract available
   
   
   
5. MASCOLINI M , Richman D, Larder B, Mellors J, et al
   Clinical implications of resistance to antiretrovirals: new resistance technologies and interpretations.
   Antivir Ther. 2008;13:319-34.
   PubMed     Related articles    Abstract available
   
   
   
6. PELLEGRIN I , Wittkop L, Joubert LM, Neau D, et al
   Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).
   Antivir Ther. 2008;13:271-9.
   PubMed     Related articles    Abstract available
   
   
   
7. MCCOLL DJ , Chappey C, Parkin NT, Miller MD, et al
   Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
   Antivir Ther. 2008;13:189-97.
   PubMed     Related articles    Abstract available
   
   
   
8. BENNETT DE , Bertagnolio S, Sutherland D, Gilks CF, et al
   The World Health Organization's global strategy for prevention and assessment of HIV drug resistance.
   Antivir Ther. 2008;13 Suppl 2:1-13.
   PubMed     Related articles    Abstract available
   
   
   
9. NGUYEN HT , Duc NB, Shrivastava R, Tran TH, et al
   HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam.
   Antivir Ther. 2008;13 Suppl 2:115-21.
   PubMed     Related articles    Abstract available
   
   
   
10. SIRIVICHAYAKUL S , Phanuphak P, Pankam T, O-Charoen R, et al
    HIV drug resistance transmission threshold survey in Bangkok, Thailand.
    Antivir Ther. 2008;13 Suppl 2:109-13.
    PubMed     Related articles    Abstract available
    
    
    
11. PILLAY V , Ledwaba J, Hunt G, Rakgotho M, et al
    Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004.
    Antivir Ther. 2008;13 Suppl 2:101-7.
    PubMed     Related articles    Abstract available
    
    
    
12. MAPHALALA G , Okello V, Mndzebele S, Gwebu P, et al
    Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006.
    Antivir Ther. 2008;13 Suppl 2:95-100.
    PubMed     Related articles    Abstract available
    
    
    
13. ABEGAZ WE , Grossman Z, Wolday D, Ram D, et al
    Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia.
    Antivir Ther. 2008;13 Suppl 2:89-94.
    PubMed     Related articles    Abstract available
    
    
    
14. KAMOTO K , Aberle-Grasse J
    Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi.
    Antivir Ther. 2008;13 Suppl 2:83-7.
    PubMed     Related articles    Abstract available
    
    
    
15. SOMI GR , Kibuka T, Diallo K, Tuhuma T, et al
    Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania.
    Antivir Ther. 2008;13 Suppl 2:77-82.
    PubMed     Related articles    Abstract available
    
    
    
16. HEDT BL , Wadonda-Kabondo N, Makombe S, Harries AD, et al
    Early warning indicators for HIV drug resistance in Malawi.
    Antivir Ther. 2008;13 Suppl 2:69-75.
    PubMed     Related articles    Abstract available
    
    
    
17. SHAFER RW , Rhee SY, Bennett DE
    Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies.
    Antivir Ther. 2008;13 Suppl 2:59-68.
    PubMed     Related articles    Abstract available
    
    
    
18. BERTAGNOLIO S , Derdelinckx I, Parker M, Fitzgibbon J, et al
    World Health Organization/HIVResNet Drug Resistance Laboratory Strategy.
    Antivir Ther. 2008;13 Suppl 2:49-57.
    PubMed     Related articles    Abstract available
    
    
    
19. MYATT M , Bennett DE
    A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings.
    Antivir Ther. 2008;13 Suppl 2:37-48.
    PubMed     Related articles    Abstract available
    
    
    
20. BENNETT DE , Myatt M, Bertagnolio S, Sutherland D, et al
    Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment.
    Antivir Ther. 2008;13 Suppl 2:25-36.
    PubMed     Related articles    Abstract available
    
    
    
21. JORDAN MR , Bennett DE, Bertagnolio S, Gilks CF, et al
    World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites.
    Antivir Ther. 2008;13 Suppl 2:15-23.
    PubMed     Related articles    Abstract available
    
    
    
22. GOHRING K , Mikeler E, Jahn G, Rohde F, et al
    Rapid semiquantitative real-time PCR for the detection of human cytomegalovirus UL97 mutations conferring ganciclovir resistance.
    Antivir Ther. 2008;13:461-6.
    PubMed     Related articles    Abstract available
    
    
    
23. SLOAN RD , Ijaz S, Moore PL, Harrison TJ, et al
    Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant.
    Antivir Ther. 2008;13:439-47.
    PubMed     Related articles    Abstract available
    
    
    
24. DEFORCHE K , Cozzi-Lepri A, Theys K, Clotet B, et al
    Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response.
    Antivir Ther. 2008;13:399-407.
    PubMed     Related articles    Abstract available
    
    
    
25. CARROUEE-DURANTEL S , Durantel D, Werle-Lapostolle B, Pichoud C, et al
    Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants.
    Antivir Ther. 2008;13:381-8.
    PubMed     Related articles    Abstract available
    
    
    
26. PRICE RW , Parham R, Kroll JL, Wring SA, et al
    Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin.
    Antivir Ther. 2008;13:369-74.
    PubMed     Related articles    Abstract available
    
    
    
27. QUIROS-ROLDAN E , Calabresi A, Lapadula G, Tirelli V, et al
    Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
    Antivir Ther. 2008;13:341-8.
    PubMed     Related articles    Abstract available
    
    
    
28. TORRESI J
    Hepatitis B antiviral resistance and vaccine escape: two sides of the same coin.
    Antivir Ther. 2008;13:337-40.
    PubMed     Related articles   
    
    
    January 2007
29. WOO HY , Park H, Kim BI, Jeon WK, et al
    Comparison of mass spectrometric analysis and TRUGENE HBV genotyping for monitoring lamivudine resistance in chronic hepatitis B patients.
    Antivir Ther. 2007;12:7-13.
    PubMed     Related articles    Abstract available
    
    
    
30. MASCOLINI M , Boucher C, Larder B, Mellors J, et al
    Key reports from the XV International HIV Drug Resistance Workshop 2006.
    Antivir Ther. 2007;12:131-45.
    PubMed     Related articles    Abstract available
    
    
    
31. DERACHE A , Traore O, Koita V, Sylla A, et al
    Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali.
    Antivir Ther. 2007;12:123-9.
    PubMed     Related articles    Abstract available
    
    
    
32. BERTAGNOLIO S , Soto-Ramirez L, Pilon R, Rodriguez R, et al
    HIV-1 drug resistance surveillance using dried whole blood spots.
    Antivir Ther. 2007;12:107-13.
    PubMed     Related articles    Abstract available
    
    
    
33. ASBOE D , Williams IG, Goodall RL, Darbyshire JH, et al
    A virological benefit from an induction/maintenance strategy: the Forte trial.
    Antivir Ther. 2007;12:47-54.
    PubMed     Related articles    Abstract available
    
    
    
34. FUNG J , Lai CL, Yuen JC, Wong DK, et al
    Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population.
    Antivir Ther. 2007;12:41-6.
    PubMed     Related articles    Abstract available
    
    
    
35. STURMER M , Dauer B, Moesch M, Haberl A, et al
    Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.
    Antivir Ther. 2007;12:25-30.
    PubMed     Related articles    Abstract available
    
    
    
36. LARDER B , Wang D, Revell A, Montaner J, et al
    The development of artificial neural networks to predict virological response to combination HIV therapy.
    Antivir Ther. 2007;12:15-24.
    PubMed     Related articles    Abstract available
    
    
    
37. MARCELIN AG , Flandre P, de Mendoza C, Roquebert B, et al
    Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.
    Antivir Ther. 2007;12:247-52.
    PubMed     Related articles    Abstract available
    
    
    
38. ALTMANN A , Beerenwinkel N, Sing T, Savenkov I, et al
    Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance.
    Antivir Ther. 2007;12:169-78.
    PubMed     Related articles    Abstract available
    
    
    
39. ZACCARELLI M , Tozzi V, Lorenzini P, Forbici F, et al
    The V118I mutation as a marker of advanced HIV infection and disease progression.
    Antivir Ther. 2007;12:163-8.
    PubMed     Related articles    Abstract available
    
    
    
40. DAM E , Lebel-Binay S, Rochas S, Thibaut L, et al
    Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.
    Antivir Ther. 2007;12:371-80.
    PubMed     Related articles    Abstract available
    
    
    
41. ILYUSHINA NA , Hoffmann E, Solomon R, Webster RG, et al
    Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
    Antivir Ther. 2007;12:363-70.
    PubMed     Related articles    Abstract available
    
    
    
42. QI X , Xiong S, Yang H, Miller M, et al
    In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.
    Antivir Ther. 2007;12:355-62.
    PubMed     Related articles    Abstract available
    
    
    
43. CHAN HL , Wang H, Niu J, Chim AM, et al
    Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
    Antivir Ther. 2007;12:345-53.
    PubMed     Related articles    Abstract available
    
    
    
44. MATHIESEN S , Dam E, Roge B, Joergensen LB, et al
    Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
    Antivir Ther. 2007;12:335-43.
    PubMed     Related articles    Abstract available
    
    
    
45. REN GL , Fang Y, Ma HH, Lei YF, et al
    The short hairpin RNA driven by polymerase II suppresses both wild-type and lamivudine-resistant hepatitis B virus strains.
    Antivir Ther. 2007;12:865-76.
    PubMed     Related articles    Abstract available
    
    
    
46. 
    Abstracts from the XVI International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. June 12-16, 2007. Barbados, West Indies.
    Antivir Ther. 2007;12:P3-4.
    PubMed     Related articles   
    
    
    
47. DI GIAMBENEDETTO S , Brocciale L, Colafigli M, Cattani P, et al
    Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study.
    Antivir Ther. 2007;12:835-9.
    PubMed     Related articles    Abstract available
    
    
    
48. CHANDLER B , Detsika M, Owen A, Evans S, et al
    Effect of transporter modulation on the emergence of nelfinavir resistance in vitro.
    Antivir Ther. 2007;12:831-4.
    PubMed     Related articles    Abstract available
    
    
    
49. CHAN HL , Wong VW, Chim AM, Choi PC, et al
    Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B.
    Antivir Ther. 2007;12:815-23.
    PubMed     Related articles    Abstract available
    
    
    
50. KARATAYLI E , Karayalcin S, Karaaslan H, Kayhan H, et al
    A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment.
    Antivir Ther. 2007;12:761-8.
    PubMed     Related articles    Abstract available
    
    
    
51. DAHL G , Sandstrom A, Akerblom E, Danielson UH, et al
    Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Antivir Ther. 2007;12:733-40.
    PubMed     Related articles    Abstract available
    
    
    
52. ANDREI G , Fiten P, Froeyen M, De Clercq E, et al
    DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions.
    Antivir Ther. 2007;12:719-32.
    PubMed     Related articles    Abstract available
    
    
    
53. STURMER M , Staszewski S, Doerr HW
    Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Antivir Ther. 2007;12:695-703.
    PubMed     Related articles    Abstract available
    
    
    
54. AOKI FY , Boivin G, Roberts N
    Influenza virus susceptibility and resistance to oseltamivir.
    Antivir Ther. 2007;12.
    PubMed     Related articles    Abstract available
    
    
    
55. CRUSAT M , de Jong MD
    Neuraminidase inhibitors and their role in avian and pandemic influenza.
    Antivir Ther. 2007;12.
    PubMed     Related articles    Abstract available
    
    
    
56. NESTOROWICZ A , Cameron S
    Key reports from the 9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV 2007.
    Antivir Ther. 2007;12:987-98.
    PubMed     Related articles    Abstract available
    
    
    
57. UY J , Brooks JT, Baker R, Hoffman M, et al
    HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
    Antivir Ther. 2007;12:957-62.
    PubMed     Related articles    Abstract available
    
    
    
58. LOHSE N , Jorgensen LB, Kronborg G, Moller A, et al
    Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.
    Antivir Ther. 2007;12:909-17.
    PubMed     Related articles    Abstract available
    
    
    
59. BONNAFOUS P , Naesens L, Petrella S, Gautheret-Dejean A, et al
    Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet.
    Antivir Ther. 2007;12:877-88.
    PubMed     Related articles    Abstract available
    
    
    
60. BRUMME CJ , Harrigan PR, Preston EC, Dong WW, et al
    Transmission of drug-resistant HIV-1 from an infected individual to a caregiver.
    Antivir Ther. 2007;12:1139-44.
    PubMed     Related articles    Abstract available
    
    
    
61. VIGNOLES M , Barboni G, Agosti MR, Quarleri J, et al
    High frequency of primary mutations associated with antiretroviral drug resistance in recently diagnosed HIV-infected children.
    Antivir Ther. 2007;12:1133-7.
    PubMed     Related articles    Abstract available
    
    
    
62. LATAILLADE M , Chiarella J, Kozal MJ
    Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
    Antivir Ther. 2007;12:563-70.
    PubMed     Related articles    Abstract available
    
    
    
63. PEUCHANT O , Capdepont S, Ragnaud JM, Aurillac-Lavignolle V, et al
    Primary resistance to enfuvirtide (T20) in recently HIV-1 infected, antiretroviral-naive patients from the ANRS Aquitaine Cohort.
    Antivir Ther. 2007;12:559-62.
    PubMed     Related articles    Abstract available
    
    
    
64. RIDDLER SA , Jiang H, Tenorio A, Huang H, et al
    A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115.
    Antivir Ther. 2007;12:531-41.
    PubMed     Related articles    Abstract available
    
    
    
65. DIETERICH DT
    Special considerations and treatment of patients with HBV-HIV coinfection.
    Antivir Ther. 2007;12 Suppl 3:H43-51.
    PubMed     Related articles    Abstract available
    
    
    
66. LOCARNINI S , Warner N
    Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.
    Antivir Ther. 2007;12 Suppl 3:H15-23.
    PubMed     Related articles    Abstract available
    
    
    
67. CHAIX ML , Desquilbet L, Descamps D, Costagliola D, et al
    Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.
    Antivir Ther. 2007;12:1305-10.
    PubMed     Related articles    Abstract available
    
    
    
68. YUEN MF , Seto WK, Chow DH, Tsui K, et al
    Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
    Antivir Ther. 2007;12:1295-303.
    PubMed     Related articles    Abstract available
    
    
    
69. ROQUE-AFONSO AM , Ferey MP, Ly TD, Graube A, et al
    Viral and clinical factors associated with surface gene variants among hepatitis B virus carriers.
    Antivir Ther. 2007;12:1255-63.
    PubMed     Related articles    Abstract available
    
    
    
70. VON HENTIG N , Babacon E, Staszewski S, Sturmer M, et al
    Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
    Antivir Ther. 2007;12:1237-46.
    PubMed     Related articles    Abstract available
    
    
    January 2006
71. MASQUELIER B , Neau D, Boucher S, Lavignolle-Aurillac V, et al
    Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Antivir Ther. 2006;11:827-30.
    PubMed     Related articles    Abstract available
    
    
    
72. CHEN CH , Wang JH, Lee CM, Hung CH, et al
    Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil.
    Antivir Ther. 2006;11:771-8.
    PubMed     Related articles    Abstract available
    
    
    
73. DESCAMPS D , Ait-Khaled M, Craig C, Delarue S, et al
    Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
    Antivir Ther. 2006;11:701-5.
    PubMed     Related articles    Abstract available
    
    
    
74. MARCELIN AG , Flandre P, Furco A, Wirden M, et al
    Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine.
    Antivir Ther. 2006;11:693-9.
    PubMed     Related articles    Abstract available
    
    
    
75. LAUNAY O , Duval X, Dalban C, Descamps D, et al
    Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
    Antivir Ther. 2006;11:889-99.
    PubMed     Related articles    Abstract available
    
    
    
76. VERHEYEN J , Litau E, Sing T, Daumer M, et al
    Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
    Antivir Ther. 2006;11:879-87.
    PubMed     Related articles    Abstract available
    
    
    
77. GREEN H , Gibb DM, Compagnucci A, Giacomet V, et al
    A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial.
    Antivir Ther. 2006;11:857-67.
    PubMed     Related articles    Abstract available
    
    
    
78. COURCAMBECK J , Bouzidi M, Perbost R, Jouirou B, et al
    Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
    Antivir Ther. 2006;11:847-55.
    PubMed     Related articles    Abstract available
    
    
    
79. GEROLAMI R , Bourliere M, Colson P, Halfon P, et al
    Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases.
    Antivir Ther. 2006;11:1103-6.
    PubMed     Related articles    Abstract available
    
    
    
80. DING C , Wong VW, Chow KC, Chan HY, et al
    Quantitative subtyping of hepatitis B virus reveals complex dynamics of YMDD motif mutants development during long-term lamivudine therapy.
    Antivir Ther. 2006;11:1041-9.
    PubMed     Related articles    Abstract available
    
    
    
81. LINDSTROM A , Ohlis A, Huigen M, Nijhuis M, et al
    HIV-1 transmission cluster with M41L 'singleton' mutation and decreased transmission of resistance in newly diagnosed Swedish homosexual men.
    Antivir Ther. 2006;11:1031-9.
    PubMed     Related articles    Abstract available
    
    
    
82. ABED Y , Baz M, Boivin G
    Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.
    Antivir Ther. 2006;11:971-6.
    PubMed     Related articles    Abstract available
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Bernd Sebastian Kamps website.    Design: